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Background
On January 28, 2005 Mylan Technologies
received FDA approval of the abbreviated new
drug application (ANDA) for their Fentanyl
Transdermal Systems products. Approved were
the 25 mcg/hour, 50 mcg/hour, 75 mcg/hour, and
100 mcg/hour products. The FDA deemed these
products bioequivalent and therapeutically
equivalent to the reference drug, Duragesic
Transdermal Systems.1
Duragesic is manufactured by Alza
Corporation and distributed by Janssen
Pharmaceutica Products.
Alza is also
manufacturing a generic fentanyl patch which is
identical to Duragesic but is distributed by
Sandoz and bears the Sandoz generic labeling. It
is bioequivalent and therapeutically equivalent to
Duragesic since it is the same product.
An evaluation of therapeutic equivalence is
assigned to pharmaceutical equivalents only if the
approved application contains adequate scientific
evidence, established through in vivo and/or in
vitro studies, that there is bioequivalence of the
product to a selected reference product.2
Currently, these two generic fentanyl patches
are the only FDA approved products but others
are under FDA review. Lavipharm Corp and
Endo Pharmaceuticals Inc. have submitted
abbreviated new drug applications to the FDA.

Product Differences and Similarities
Mylan’s fentanyl transdermal system differs
from the Alza-produced Duragesic and Sandoz
generic patches. Mylan patches are smaller in
size compared with the equivalent Duragesic or
Sandoz products. The primary difference is the
drug reservoir.3,4
Mylan uses a solid matrix fentanyl-containing
silicone adhesive that is sandwiched between a
backing film and protective liner. Just prior to use
the protective liner is removed and the ratecontrolling fentanyl matrix is applied to the skin.4

Duragesic and the Sandoz generic have a
liquid fentanyl reservoir. The system consists of
an external backing layer, the reservoir of fentanyl
and alcohol USP gelled with hydroxyethyl
cellulose, an ethylene-vinyl acetate copolymer
membrane, a fentanyl-containing silicone
adhesive, and a protective liner. This liner is
removed prior to application. In this system the
ethylene-vinyl copolymer membrane controls the
drug delivery rate.3
Janssen distributes the only 12.5 mcg/hour
product. There are no currently available generic
equivalents for this product. It was approved by
the FDA in February 2005.
All generic products have the same prescribing
information as Duragesic in their labels.3,4
All used patches contain residual fentanyl in
their matrices and should be folded so that the
adhesive sides adhere to each other.3,4 All generic
products create the same diversion potential as the
brand name.5
Based on the average wholesale drug cost, the
generic fentanyl patches cost approximately six
percent less than Duragesic patches.6

Commentary
With the availability of generic fentanyl
patches, formulary-driven insurance plans and
group buying contract decisions may necessitate
conversion from the Duragesic patch to a generic
patch. Because of the FDA AB rating, patch
conversion concerns should be minimized.1
There have been reports posted on the
American Pain Foundation’s website describing
differences in analgesic efficacy and side effects.7
Concerns mentioned in postings to their
discussion board state that both the Mylan and
Sandoz generics are not as effective. Some
postings also describe that there are more side
effects such as nausea and vomiting with the
generic versions.7
More. . .

Copyright © 2005 by Therapeutic Research Center
Pharmacist’s Letter / Prescriber’s Letter ~ P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.pharmacistsletter.com ~ www.prescribersletter.com

(Detail-Document #210504: Page 2 of 2)

Issues of efficacy may be perceived due to the
smaller size of the Mylan patches as compared to
the Duragesic patches and also the fact that they
are generics. Some believe that generics don’t
work as well as the brand name product. Postmarketing investigation of reports may reveal
actual differences. An individual’s perception of
pain and pain-relief is subjective and must be
evaluated with reference to the person’s pain
control goal. Encourage reporting of product
problems. To report product problems, call the
FDA MEDWATCH program at 1-800-FDA-1088.
The MEDWATCH program is also available online at www.fda.gov/medwatch. Or report to the
USP Medication Errors Reporting Program in
cooperation with the Institute for Safe Medication
Practices
at
1-800-23-ERROR
or
at
www.usp.org/patientSafety/reporting/mer.html.
Be aware of the potential for actual or
perceived differences when switching fentanyl
patch products. Patients who have always used
the Duragesic patch may need to be monitored
more closely when switching to a generic patch.
During the conversion to a generic patch some
patients may require short-acting analgesics for
breakthrough pain.
Users of this document are cautioned to use their own
professional judgment and consult any other necessary

or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.
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